Table 2.

Primary analysis and sensitivity analysis of overall survival (OS) and time to next treatment (TTNT) in the gefitinib and erlotinib cohorts.

	Gefitinib				Erlotinib
	Univariate analysis		Multivariable analysis		Univariate analysis		Multivariable analysis
	HR (95% CI)	P value	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Primary analysis
OS
Non-user	1.00		1.00		1.00		1.00
H2RA	1.19 (1.10–1.29)	< 0.0001	1.14 (1.05–1.24)	0.003	1.16 (1.02–1.32)	0.027	1.00 (0.87–1.15)	0.992
PPI	1.50 (1.37–1.65)	< 0.0001	1.58 (1.42–1.76)	< 0.0001	1.53 (1.32–1.76)	< 0.0001	1.54 (1.30–1.82)	< 0.0001
TTNT
Non-user	1.00		1.00		1.00
H2RA	0.88 (0.82–0.95)	0.001	0.92 (0.85–1.00)	0.049	0.91 (0.81–1.02)	0.110	0.83 (0.73–0.94)	0.004
PPI	1.13 (1.04–1.24)	0.006	1.37 (1.24–1.52)	< 0.0001	1.08 (0.94–1.23)	0.288	1.19 (1.01–1.39)	0.033
Sensitivity analysis
OS
Non-user			1.00				1.00
H2RA			1.16 (1.06–1.27)	0.002			0.96 (0.83–1.12)	0.613
PPI			1.65 (1.47–1.86)	< 0.0001			1.56 (1.30–1.88)	< 0.0001
TTNT
Non-user			1.00				1.00
H2RA			0.94 (0.86–1.02)	0.135			0.80 (0.70–0.92)	0.002
PPI			1.53 (1.37–1.72)	< 0.0001			1.19 (1.00–1.42)	0.049